BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX

BioCryst to Present at Upcoming Investor Conferences

· Issued by BioCryst Pharmaceuticals, Inc. via GlobeNewswire

Summary by 6ix AI

BioCryst Pharmaceuticals, a biotechnology company developing medicines for hereditary angioedema and other rare diseases, plans to present at two investor conferences on November 18, 2026 and December 1, 2026.

Key details

  • 2026 Jefferies Global Healthcare Conference in London: Wednesday, November 18, 2026, at 8:30 a.m. ET.
  • 9th Annual Evercore Healthcare Conference in Coral Gables, FL: Tuesday, December 1, 2026, at 8:45 a.m. ET.
  • Live audio webcasts and replays of the presentations will be available in the Investors & Media section of BioCryst's website.

6ix AI wrote this summary from the release below and checked it against the release.

RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:

  • 2026 Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026, at 8:30 a.m. ET.
  • 9th Annual Evercore Healthcare Conference in Coral Gables, FL, on Tuesday, December 1, 2026, at 8:45 a.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor and is advancing a pipeline of potential first-in-class or best-in-class therapeutics for rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:

Investors:
[email protected]

Media:
[email protected]


View original source (GlobeNewswire)BioCryst Pharmaceuticals, Inc. on 6ix

Story so far

Earlier from BioCryst Pharmaceuticals

All BioCryst Pharmaceuticals news releases